Repligen (RGEN)
(Real Time Quote from BATS)
$161.08 USD
-0.59 (-0.37%)
Updated Aug 5, 2024 02:34 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Repligen (RGEN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$190.18 | $220.00 | $160.00 | 17.63% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Repligen comes to $190.18. The forecasts range from a low of $160.00 to a high of $220.00. The average price target represents an increase of 17.63% from the last closing price of $161.67.
Analyst Price Targets (11)
Broker Rating
Repligen currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 69.23% and 7.69% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.54 | 1.58 | 1.58 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/31/2024 | UBS | Dan Leonard | Strong Buy | Strong Buy |
7/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/30/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
6/18/2024 | Guggenheim Securities | Subbu Nambi | Not Available | Hold |
6/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/2/2024 | William Blair | Matt Larew | Strong Buy | Strong Buy |
5/1/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
4/19/2024 | Craig-Hallum | Matthew G Hewitt | Strong Buy | Strong Buy |
3/1/2024 | The Benchmark Company | Robert Wasserman | Hold | Hold |
2/15/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 13 |
Average Target Price | $190.18 |
LT Growth Rate | 19.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | 0.33 |